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Body fat distribution as a
risk factor for osteoporosis
Renee Blaauw, Eisa C. Albertse, Stephen Hough
Objective. The aim of this study was to compare the body
fat distribution of patients with osteoporosis (GP) with that
of an appropriately matched non-GP control group.
Design. Case control study.
Setting. Department of Endocrinology and Metabolism,
Tygerberg Hospital.
Participants. A total of 56 patients with histologicatly
proven idiopathic GP, of whom 39 were women (mean age
61 ± 11 years) and 17 men (49 ± 15 years), were compared
with 125 age- and sex-matched non-OP (confirmed by
dual energy X-ray absorptiometry) subjects, 98 women
(60 ± 11 years) and 27 men (51 ± 16 years).
Outcome measures. Anthropometric data, including
weight, height, skinfold measurements, mid-upper arm,
waist and hip circumferences, as well as elbow breadth.
Results. The men and women with OP were significantly
shorter (P = 0.04 and P = 0.03 respectively) and of lower
body mass (P = 0.04 and P = 0.02 respectively) than the
control subjects, although their mean body mass indices
were comparable. The OP population had significantly
lower skinfold, elbow breadth and ann circumference
values, although the majority of subjects in both groups
fe/l within the 15 - 85th percentiles. Despite their lower
body mass, both the OP women (P = 0.009) and men
(P =0.002) had significantly higher waist/hip ratios than
corresponding controls.
Conclusion. Whatever the underlying pathogenesis, this
new finding suggests that, should these results be
confirmed by larger studies, OP can be added to the list of
diseases associated with a waist fat distribution.
S Atr Med J 1996; 86: t081-1084.
Osteoporosis (OP) is an extremely common disorder,
characterised by a decrease in bone mineral density (BMO)
that results in an increased propensity to fracture which
most often involves the spine, hip or wrist. 1•3 The
pathogenesis and risk factors which predispose to the
development of OP, however, remain ill-defined.
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In the past, most epidemiological studies that examined
the association between obesity and disease considered
only total adipose tissue and ignored its distribution.
Recently it has become apparent that it is not obesity per
se, but the regional distribution of adipose tissue, that
correlates with many obesity-related morbidities including
atherosclerosis, hypertension, hyperlipidaemias and
diabetes mellitus.4-8
The anatomical distribution of adipose tissue differs
between men and women in both normal and obese
individuals, suggesting that sex hormones are involved in
the regulation of adipose tissue metabolism.5--10 Upper body
(android or waist) obesity, which is typically observed in
men, is associated with hyperandrogenism, whereas lower
body (gynoid or hip) obesity is far more common in women,
suggesting an oestrogenic influence.':>-12 Moreover, upper
body obesity has been shown to be associated with
hypercortisolism and classically occurs in patients with
Cushing's syndrome. 13 Since hypogonadism and
hypercortisolaemia are well-known causes of GP, we
questioned whether this disease was also associated with
changes in the regional distribution of adipose tissue. The
aim of this study was therefore to compare the body fat
distribution of patients with proven idiopathic GP with that of
an appropriately matched non-ap control group.
Materials and methods
Subjects
All the subjects in the ap group had proven idiopathic OP
on dual-energy X-ray absorptiometry (OEXA), as well as a
clinical, radiological, biochemical and histological
(quantitative histomorphometry after time-spaced
tetracycline labelling of undecalcified bone biopsies)
work-up, thereby excluding individuals with (I) secondary
OP and (if) metabolic bone diseases other than OP, e.g.
osteomalacia, hyperparathyroidism. The group consisted of
56 Caucasian subjects, consecutively admitted to our
Endocrine Unit for evaluation of their ap, of whom 17 were
men and 39 women. The mean age of the men was 49
(±15) years and that of the women 61 (±11) years.
The control group consisted of 125 age- and sex-matched
Caucasian subjects of whom 27 were men and 98 women,
of mean ages 52 (±16) years and 60 (±10) years respectively.
The absence of osteopenia in this group was confirmed by
DEXA
Methods
Bone mass was measured by means of OEXA (Hologic
OOR-1000) in all the SUbjects and included the lumbar spine
(L1 - L4) and hip. Osteopenia was diagnosed if the BMD
was found to be decreased by more than 1.5 standard
deviations (SOs) in subjects younger than 40 years, or by
more than 2.0 SOs in those over 40 years of age, compared
with the BMO of young normal subjects. '4
Anthropometric data were obtained from every subject
and included weight, height, skinfold thickness
measurements (triceps, biceps, subscapular, supra-iliac),
mid-upper arm circumference, waist and hip circumference,
as well as elbow breadth determinations.
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Table I. Bone mineral density of subjects (gJcm~ (mean (SO))
Vertebrae
L1 - L4 0.72 (0.10)" 1.11 (0.17) 0.72 (0.13)1 1.15(0.13)
Femoral
Neck 0.60 (0.09)" 0.88 (0.13) 0.64 (0.12)1 0.95 (0.08)
Warn's trian91e 0.39 (0.11)" 0.71 (0.17) 0.39 (0. 16)T 0.69 (0.10)
Troch 0.50 (0.10)" 0.76 (0.09) 0.54 (0.08)1 0.80 (0.08)
Total 0.64 (0.20)" 1.02(0.13) 0.74 (0.12)t 1.09 (0.06)
• P=O.OOOl.
tP = 0.008.
The mean waist/hip ratio (WHR) for both control and
osteoporotic men was nonmal (below 1.0). The WHR for
control women of 0.81 (0.05) marginally exceeded the
accepted upper limit of 0.80, whereas osteoporotic women
had a mean WHR of 0.87 (0.1). In fact, both the osteoporotic
men (P = 0.002) and women (P = 0.0009) had significantly
higher WHRs than their corresponding controls (Table 11).
The odds ratio that a man with a waist fat distribution had
GP was 8 times higher than that of a man with a hip fat
distribution (95% Cl: 1.037 - 61.731), whereas for women rt
was 1.6 times higher (95% Cl: 0.751 - 3.588).
had a significantly lower body weight than the control
subjects. The GP men (P = 0.04) and women (P = 0.03) were
also significantly shorter than controls, although all subjects
stili maintained an upright posture. Body mass index (BMI)
values were, however, comparable. Elbow breadth, an
indicator of frame size, was significantly lower in the GP
SUbjects compared with controls, although mean values for
both groups were indicative of a medium frame size. The GP
group had significantly lower skinfold and circumference
values for most of the measurements, although the majority
of subjects in both 9roups fell within the 15 - 85th
percentiles. From these data it is clear that both the GP and






The following methods were employed: (I) weight - the
SUbjects were weighed with the minimum of clothes on, to
the nearest 0.1 kg;15 Qf) height was measured with a sliding
headpiece to increase the accuracy of the readings, which
were taken to the nearest 0.1 cm;'5 (iil) skinfolds were
measured with a Harpenden caliper. All measurements were
taken to the nearest 0.1 mm on the right side of the body:
biceps - over the midpoint of the biceps muscle, triceps -
over the triceps muscle, midway between the acromial
process of the scapula and the olecranon, subscapular-
just below the tip of the scapula, at 4SQ to the vertical,
supra-iliac - just above the iliac crest on the mid-axillary
line;'5 (iv) mid-upper arm circumference was measured at the
same point as the triceps skinfold;15 (v) waist circumference
was detennined in the erect position, around the waist
through a point one-third of the distance between the
xiphoid process and the umbilicus;5 (VI) hip circumference
was assessed in the erect position, around the hips through
a point 4 cm below the sUperior anterior iliac spine.s Every
effort was made to ensure that the tape was horizontal at
the back while waist and hip circumference values were
determined. These measurements were taken without
ciothing; (vii) elbow breadth, the greatest breadth across the
elbow joint, was measured with a sliding caJiper to the
nearest 0.1 cm. 1&
All measurements were made in triplicate by the same
observer, and the results averaged.
Statistical analysis included the Wilcoxon signed-rank
test, the Spearman correlation coefficient and the Cochran-
Mantel-Haenszel test to determine odds ratios and to obtain
95% confidence intervals (95% Cls)."
Results
The BMD of the lumbar spine and various hip areas of both
the men and the women with OP was significantly lower
than in the comesponding controis (Table I).
Table 11 lists the anthropometric data of all the subjects.
Both the men (P =0.04) and the women (P =0.02) with GP
Table 11. Anthropometric data on subjects (mean ISOI)
Women Men
Measurements GP Control P-vaJue OP Control P-vaJue
Body mass (1<g) 64 (12) 69 (12) 0,02 70 (12) TT (12) 0.04
Hei9ht (cm) 1.62 (0.06) 1.64 (0.07) 0.03 1.71 (0.07) 1.77 (0.08) 0.04
BMi 24(5) 26 (5) 0.17 24 (3) 25 (3) 0.22
WHR 0.87 (0.11) 0.81 (0.05) 0.0009 0.96 (0.06) 0.89 (0.06) 0.002
Middle circumference (cm) 64.9 (15.3) 83.9 (10.7) 0.91 85.6 (12.2) 90.9 (9.6) 0.18
Hip circumference (cm) 97.9 (13.4) 103.9 (10.3) 0.01 89.3 (12.3) 100.9 (6.5) 0.001
8bow breadth (cm) 6.4 (0.8) 6.7 (0.4) 0.03 7.1 (0.3) 7.4 (0.4) 0.007
Biceps (mm) 12.0 (5.7) 12.6 (5.9) 0.69 5.6 (2.9) 6.5 (2.5) 0.10
Triceps (mm) 20.0 (6.4) 23.4 (6.3) 0.01 10.7 (5.3) 13.2 (2.9) 0.01
Subscapular (mm) 16.3 (6.7) 16.8 (7.1) 0.96 12.3 (4.6) 16.4 (6.4) 0.03
Supra-iliac (mm) 18.2 (8.5) 19.9 (9.0) 0.52 13.1 (5.5) 16.6 (5.3) 0.07
Mid-upper arm circumference (cm) 29.0 (4.3) 31.1 (3.6) 0.0005 29.2 (2.0) 31.4 (3.0) 0.008
BMl = body mass~ WHA :: waistIhip ratio.
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Discussion and conclusions
The relationship between body mass and BMD is well
established, and a low body mass is classically regarded as
a risk factor for the development of Op'1-3·1s.-20 80th weight
and adiposity could affect BMD in a number of ways. In
heavy sUbjects, weight imparts a load factor on weight-
bearing bones, resulting in the stimulation of osteoblastic
bone formation. 21 In postmenopausal women, adipose tissue
serves as the site of peripheral conversion of
androstenedione to metabolically more active oestrogens,
known to inhibit bone resorption.20-23 Adiposity cannot,
however, be regarded as a homogeneous disorder anymore,
and the clinical significance of regional fat distribution is
now well established.
Because a significant correlation exists between the intra-
abdominal/subcutaneous fat ratio and the WHR, the latter
has become a useful indirect measure of visceral adiposity
and correlates well with many obesity-related morbidities
regardless of whether the BMI is high or IOW,l3,24
A number of metabolic abnormalities have been shown to
be associated with upper body (android) obesity; many of
these may have potentially deleterious effects on skeletal
integrity. An upper body fat distribution is associated with
increased circulating glucocorticoid levels and Bjorntorp has
hypothesised that it is primarily a maladaptive hypothalamic
response to various environmental stressors that results in
increased activity along the corticotrophin (ACTH)-cortisol
axis in these subjects,25 An android profile of fat deposition
is well established in patients with Cushing's syndrome and
it has been suggested that the influence of high cortisol
levels on abdominal fat cells could be due to the high
density of glucocorticoid receptors in this depot_2E.27 Since
glucocorticoid excess is known to inhibit bone formation
directly,<'ll.2S enhance parathyroid hormone-mediated bone
resorption,29 impair renal vitamin 0 hydroxylation and
intestinal calcium absorption,2.29 and decrease circulating
levels of sex hormones,30~' the association between
abdominal obesity and a decreased BMD, noted in the
present study, may not be surprising.
Women with upper body obesity have increased serum
free testosterone and decreased sex hormone-binding
globulin levels.8-11.:l2-34 Conversely, the serum and tissue levels
of oestrogens and progesterone seem to be related to lower
body fat accumulation with little influence on truncal-
abdominal fat. 55 Abdominal adiposity is also observed in
hyperandrogenic conditions like the polycystic ovary
syndrome,30: idiopathic hirsutism4,8.34,36 and the menopause.35
In women with an android fat distribution there is evidence
of decreased sex steroid secretion, which may result from
aberrations of gonadotrophin release. 25 Moreover,
hypercortisolaemia is known to decrease circulating levels of
female sex hormones.30 In men, central obesity is associated
with ageing, low levels of testosterone31 ,3l1 and increased
peripheral aromatisation of androgens to oestrogens. l1 .35 In
both sexes, upper body obesity therefore seems to be
associated with relative hypercortisolism and decreased sex
hormone levels. Oestrogen deficiency is a known risk factor
for the development of GP in women. The effect of
oestrogen on bone was initially thought to be indirectly
mediated via its activation of vitamin 0 metabolism,
stimulation of intestinal calcium absorption, or increase in
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circulating levels of the anti-resorptive hormone, calcitonin,
and protection against parathyroid hormone-mediated bone
resorption.1-3 Recently, however, oestrogen receptors have
been noted in human bone cells.:N Hypogonadism is also a
well-known cause of osteoporosis in men, and androgens
have potent anabolic effects on skeletal tissue.40
We acknowledge that vertebral compression fractures can
result in decreased height and a change in posture.
However, even though the osteoporotic subjects were
significantly shorter than the controls, no posture changes
resulting from clinical kyphosis, which might give rise to a
subsequent relatively larger abdominal circumference, were
observed in this group. We do not believe, therefore, that the
findings are in any way influenced by anatomical posture
changes caused by kyphosis.
Finally, we should take cognisance of the fact that regional
fat distribution, like GP, also has significant genetic
determinants.J5 In this regard, the recent observation that
relative truncal adiposity is influenced by a major locus and
polygenic inheritance is of interest.41 Speculation on the
pathophysiological basis of the observed association
between osteoporosis and regional fat distribution is
therefore not difficult - further studies are needed, however,
before the findings of the present study can be placed in
their proper perspective.
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Formulary and funding
implications of the gap
between the national
Essential Drugs List and
current prescribing in a
large health maintenance
organisation
Alan D. Rothberg, Laubi Waiters
Background. The Department of Health has prepared an
Essential Drugs Ust (EDL) for public sector
implementation in 1996 and future extension to the private
sector. Stakeholders have been consulted to ensure that
the EDL achieves its objectives of safety, efficacy and
quality at the lowest possible cost, while providing
coverage for 90 - 95% of the common and important
conditions in the country.
This study was undertaken to gain insight into the current
use of EDL products by 200 general practitioners (GPs)
servicing a large health maintenance organisation (HMO).
Methods. Approximately 120 000 prescriptions were
reviewed and the use of specified EDL medicines, other
forms of EDL medicines and non-EDL medicines was
analysed for several pharmacological groups. These
included antibiotics and medicines for the cardiovascular,
musculoskeletal, central nervOUSr respiratory and gastro-
intestinal systems.
To gauge potential savings to the private sector through
the purchase of EDL products at state tender prices,
current prices of a random sample of EDL products were
compared.
Results. In the areas reviewed, only 22.4% of current GP
prescriptions included EDL items; a further 19.6%
included 'other forms of EDL' items. Simply obtaining
those EDl products that are currently prescribed at state
tender prices would recluce costs by almost 20%, while
extending the use of EDl products might save in excess
of 70% on private sector GP prescriptions.
Conclusions. Assuming that all prescriptions were
clinically indicated, the 'gap' between the EDL and
medicines prescribed indicates that debate will be
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